- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Differentiating PDTs from Wellness Apps and Evaluating Efficacy
Diana Brixner, PhD, and Ashley Peterson, MHA, explore the distinctions between prescription digital therapeutics (PDTs) and wellness mobile apps, addressing the role of insurance coverage and the clinical validation requirements that payers consider when determining whether to cover PDTs as a treatment modality.
EP: 1.Differentiating PDTs from Wellness Apps and Evaluating Efficacy
EP: 2.Payer Needs and Strategies for Evaluating and Covering PDTs
EP: 3.Payers Review Process and Effective Strategies for PDT Coverage
EP: 4.Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions
EP: 5.Dawn of the Age of Adopting PDTs
EP: 6.Identifying the Most Impactful Disease Areas and Patient Populations for PDTs
EP: 7.Evolving Commercialization and Distribution Models for PDTs
EP: 8.Promoting Appropriate PDT Prescribing Through Provider Education and Support
EP: 9.Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs
EP: 10.Optimizing Benefit Design and Implementation for Improved PDT Access
EP: 11.PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
